Printer Friendly

Core Oncology Acquires Brachytherapy Business.

SANTA BARBARA, Calif. -- On June 8, 2007, Core Oncology announced it has closed on its acquisition of Mills Biopharmaceuticals, LLC, the brachytherapy division of Coloplast A/S.

Founded in 1992, Mills Biopharmaceuticals, LLC of Oklahoma City, Okla., is the third largest domestic supplier of Iodine 125 and Palladium Pd-103 seeds for low dose prostate brachytherapy treatment. ProstaSeed([R]) has been commercially available since April of 1999 and is both CE marked and manufactured at ISO 9001:2000 standards. In early 2003 the company was acquired by Mentor Corporation. In June 2006 Coloplast acquired Mills Biopharmaceuticals as part of the urology portfolio from Mentor.

Travis Gay, President and CEO of Core Oncology, stated, "We have a leadership position today in the growing prostate brachytherapy market and look forward to building sales around the world as we continue to expand this product line and focus on the growing radiation therapy market. Through this acquisition, we now have the most advanced brachytherapy manufacturing plant in the industry, the lowest cost of assets, and a loyal base of customers at the leading-edge of therapy in this arena."

Core Oncology was formed by the senior management of the existing brachytherapy business and Compass Capital (based near Seattle, Washington) for the purpose of acquiring the brachytherapy business from Coloplast. Compass negotiated the purchase, helped to develop Core's strategic business plan and model, and facilitated the necessary capital. Compass will continue to provide Core with advisory and management services going forward.

Core Oncology develops and manufactures specialized medical products, which it markets throughout the world. This release contains, in addition to historical information, forward-looking statements. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in the forward-looking statements.
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jun 12, 2007
Previous Article:CirTran CEO Sees 'No Reason or Rationale' for Recent Dip in Stock Price.
Next Article:Youbet Sets Another Triple Crown Record.

Related Articles
South Lane chief faces second firing.
Updates from agency leaders.
Phil Johnson coaches clients and agency to successes.
Lights, camera, learning.
Dynamic CRM from Microsoft.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters